A Study of LY4064809 in Healthy Adult Chinese Participants

NCT ID: NCT07247357

Last Updated: 2026-01-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-10-24
• Study Completion Date: 2025-12-16

Brief Summary

The main purpose of this study is to measure how much LY4064809 gets into the bloodstream and how long it takes the body to eliminate it in healthy participants. It also looks at safety and tolerability in healthy participants. The study drug will be administered orally. The study will last approximately 21 days, excluding screening.

Conditions

Healthy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

LY4064809

LY4064809 administered orally

Group Type: EXPERIMENTAL

LY4064809

Intervention Type: DRUG

administered orally

Interventions

LY4064809

administered orally

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Are native Chinese. To qualify as a native Chinese for the purpose of this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China
• Are overtly healthy as determined by medical evaluation, including medical history, physical examination, vital signs, and electrocardiogram (ECG) at screening and admission
• Have clinical laboratory test results within the normal range for the population or investigative site, or with abnormalities deemed not clinically significant by the investigator at screening
• Have a body mass index within the range 18 to 32 kilogram per square meter (kg/m²)

Exclusion Criteria

• History or presence of any of the following conditions, deemed clinically significant by the investigator (or designee), which may significantly alter the absorption, metabolism, or elimination of drugs, constitute a risk when taking the study intervention, or interfere with the data interpretation:

• metabolic disease, including congenital non-hemolytic hyperbilirubinemia, for example, Gilbert syndrome
• bile duct disease, including removal of the gall bladder
• digestive system disease
• blood disease
• disease of the nervous system
• significant history of, or presence of, liver disease, including any abnormal liver function tests, as defined by aspartate aminotransferase, alanine transaminase, or transducin beta-like above the 1.5× upper limit of normal range per the laboratory's reference ranges at screening, or
• clinically significant, active cardiovascular disease or history of heart attack within 6 months prior to the planned start of LY4064809
• Have a 12-lead ECG abnormality at screening or admission
• History of a major surgical procedure within 30 days prior to screening
• Diagnosed or treated cancer within 5 years prior to screening
• Have known allergies to LY4064809 or related compounds

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company

INDUSTRY

Sponsor Role: collaborator

Eli Lilly and Company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Role: STUDY_DIRECTOR

Eli Lilly and Company

Locations

Lilly Centre for Clinical Pharmacology

Singapore, , Singapore

Countries

Singapore

Other Identifiers

J6M-MC-JSGE

Identifier Type: OTHER

Identifier Source: secondary_id

27745

Identifier Type: -

Identifier Source: org_study_id